Skip to main content
Premium Trial:

Request an Annual Quote

Concert Genetics, Trapelo Health to Integrate Technology for Oncology Decision Support

NEW YORK – Concert Genetics and Trapelo Health have agreed to integrate their technology to offer more comprehensive evidence-based molecular decision support for oncology, the companies said Thursday. They will deliver the service through Nashville, Tennessee-based Concert's network of health plans and genomics laboratories.

The firms said that their partnership seeks to improve connectivity and transparency to help clinicians make more informed decisions on molecular testing, cancer treatment, and recommending patients for clinical trials.

Burlington, Massachusetts-based startup Trapelo Health makes a clinical decision support system that links healthcare providers, testing laboratories, and payors, giving them access to molecular testing information and results interpretation in order to optimize utilization of molecular testing services and offer the most appropriate care to patients

"An increasing number of treatment decisions require both familial and somatic testing. Our collaboration gives stakeholders the resources and expertise to effectively manage genomic-informed decision making in the new age of cancer care," Trapelo CEO Clynt Taylor said in a statement.

"Achieving the promise of precision medicine requires bringing exactly the right data to bear at the moment of truth, when diagnosis is determined and treatment decisions are made," Concert Genetics CEO Rob Metcalf added. "Together, Concert and Trapelo can improve the quality and clarity of information available at that moment for the benefit of all stakeholders, especially the patient."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.